Is there any difference in efficacy between brand Clozaril and generic Clozapine

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

ELOVL4

Doc from the Ozarks
10+ Year Member
Joined
Apr 9, 2009
Messages
50
Reaction score
0
I have a patient who is on generic Clozapine 400 mg po bid. the patient has not responded until now . Still very withdraw, showing negativism, mute.
I know there could be compliance issue but at this high dose of Clozapine, patient should have been responded.

I am wondering is there any difference in efficacy between the Clozaril and generic Clozapine.

Members don't see this ad.
 
You could check a clozapine level. Does the patient smoke? It may be helpful to verify a "therapeutic" plasma [clozapine] before declaring a failed trial with generic clozapine.

Branded versus generic clozapine: bioavailability comparison and interchangeability issues.

Lam YW, Ereshefsky L, Toney GB, Gonzales C.
Source

Department of Pharmacology, University of Texas Health Science Center at San Antonio, 78229-3900, USA. [email protected]

Abstract

Clozapine has been the treatment of choice for patients with refractory schizophrenia. Generic clozapine has recently become available, because of a waiver of the usual criteria for establishing bioequivalence. However, there are biopharmaceutical, bioavailability, and clinical concerns related to the generic formulation raised by both clinicians and academic researchers. We conducted a prospective, randomized, crossover study to evaluate steady-state pharmacokinetics, pharmacodynamics, and tolerability of generic clozapine (Zenith Goldline Pharmaceuticals) versus Clozaril (Novartis Pharmaceuticals) in schizophrenic patients. A preliminary report of the pertinent bioavailability results is presented here. Despite comparable mean plasma concentration-time curves, significant differences were found in the primary pharmacokinetic parameters of the 2 formulations in almost 40% of patients. Such intraindividual differences raise the issue of average bioequivalence versus individual bioequivalence and the implication for interchangeability of different clozapine formulations. The decision to switch a patient from branded to generic clozapine should be made on an individual basis with special emphasis on clinical outcome, and patients should be monitored closely during the transition.

______________________________________________________________________________________________________________________

Generic clozapine: a cost-saving alternative to brand name clozapine?

Tse G, Thompson D, Procyshyn RM.
Source

Department of Pharmacy, Riverview Hospital, Port Coquitlam, British Columbia, Canada.

Abstract

As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the others as the agent most efficacious for the treatment of refractory patients. Since the patent for Clozaril (Novartis) expired in 1998, three manufacturers of generic clozapine have submitted abbreviated new drug applications to the US FDA for review and approval to market a generic clozapine product. In each case, the US FDA deemed the generic formulations to be bioequivalent to the brand name Clozaril. Apart from case reports, industry-sponsored studies have been conducted comparing Clozaril with two generic formulations. In one case, a generic formulation of clozapine manufactured by Creighton Products Corporation (formerly a subsidiary [generic house] of Sandoz Pharmaceuticals) was found to be bioequivalent to Clozaril. On the other hand, studies (sponsored by Novartis) have challenged the bioequivalence, therapeutic equivalence and interchangeability between Clozaril and a generic formulation manufactured by Zenith Goldline Pharmaceuticals (now IVAX Corporation). The IVAX Corporation-sponsored studies refuted these claims citing data from two patient registry database studies and one small clinical trial. Apart from a single in-house bioequivalence study, no further investigations have been conducted with a third generic formulation manufactured by Mylan Pharmaceutical. Although the clinical significance of the above discrepancy is obvious, what is less than obvious is the pharmacoeconomic implications that arises from this debate. Clearly, if the brand name and generic formulations are 'truly' bioequivalent, then the cost savings realised would be the difference in acquisition cost. On the other hand, if the various formulations are not bioequivalent, then the economic benefits of a lower-priced generic formulation may be compromised. In the worst-case scenario, if a patient decompensates as a result of switching from Clozaril to a generic formulation, the added direct costs (i.e. hospitalisation) and indirect cost (i.e. lost productivity) will most certainly offset any cost savings resulting from the use of a generic formulation. Until further studies have been conducted, we suggest that patients who are treatment refractory and stabilised on Clozaril are not switched to a generic formulation. On the other hand, if a patient is stabilised on Clozaril and not treatment refractory, then cautious switching to a generic formulation may be reasonable. Finally, initiating a generic formulation in a 'clozapine-naïve' individual would be appropriate. The cost implications related to these recommendations will depend on the success or failure of treatment.
 
Last edited:
Thank you for your reply. The articles are very helpful.
The patient is not a smoker, is in inpatient unit.
 
Members don't see this ad :)
Per FDA guidelines, as far as I'm aware, generics should be the same medication, all things being equal, as the trade-name meds. The FDA regulates generics just like they regulate the trade-names, including guidelines where the FDA occasionally randomly picks out a med, puts it under a spectrometer to double-check to see if the generic med is actually what the company claims it to be.
Here's just one article about it. I've read the same data from several difference sources including medical journals, Consumer Reports, even business programs.

http://www.ehow.com/facts_7329312_fda-guidelines-bioequivalence.html

Okay, here's where I can actually teach you something you won't learn in a journal, textbook, or classroom. Do I believe the above? Yes. But I have seen some patients, though it's rare, be able to tolerate one med but not another that are supposed to be the same med, but one is generic and the other is not. It's not common, but I tend to get at least one person every few months if not more where this happens.

E.g. The person can tolerate Citalopram but not Lexapro, or the person can tolerate Citalopram from Walgreens but not from CVS.

An educated doctor, but not an open-minded one may accuse the patient of lying or simply having a psychosomatic problem to the new med. This is hogwash in some cases. I've seen patients switch pharmacies not expecting there to be any difference but get a different reaction with the different meds despite the FDA guidelines.

How can this be?

Medications usually aren't the pure medication in and of itself.

Take Prozac (flouxetine) for example....

PAR07340_50840_5.JPG


prozac10c.jpg


Huh, Why is one a capsule and one a pill? It's all in the manufacturing. When one takes the capsule, you're taking a gel capsule that's made of material other than fluoxetine. When you take the pill, the medication (fluoxetine) is mixed with a filler that allows the medication to survive the rigors of the GI tract and get absorbed.

Simply put, one may have a bad reaction to the filler or it's official name, an "excipient."

http://en.wikipedia.org/wiki/Excipient

When one has an allergic reaction to a "medication", that person may in fact not be allergic to the bioactive pharmacological agent known as the medication, but merely a bad reaction to the excipient. It's possible one may be able to take the medication from another manufacturer that doesn't use the same excipient.

Now here is where I criticize doctors. Several doctors don't know this. So when patients have a bad reaction to a generic but not the trade-name or vice-versa, some doctors flip out, accusing their patients of lying or being hypochondriacs. The doctor, knowing more about medicine in general, but not the entire picture, often times feel they are always right and their patients are always under them in terms of specific medical knowledge.

I've seen several patients that actively looked up their disease on Internet forums and actually taught me a thing or two about their situation not taught in the medical textbooks. E.g. I had a patient who had an iatrogenic dependence on benzodiazepines thanks to a previous doctor that gave it out like candy, and I was weaning her off of it. She developed a rash during the taper-down. I never recalled seeing this phenomenon in the texts and when she did her own research, she found that could happen from a taper-down. After I did some more looking into it, I did find articles showing this though they were hard to find and not in the textbooks.

An egocentric doctor would've automatically thought this patient was lying, or at least misinformed.

The bottom line is that in medicine, the data can only suggest what usually goes on more often than not. If a person has a headache, yes ibuprofen usually will work, but you can't give it to 100% of people expecting it to work the same for everyone. A patient tells you they lost their script of Xanax, and asks you to replace it, you can't immediately assume they're lying. Yes--I would not replace it because they are likely lying, but there's a possibility they may not be. In cases like this, I tell the patient (and I hardly ever give out Xanax anyway, and when I do it's only because I'm tapering a patient off of it from some other doctor that started them on it) that I am not trying to judge against them, but based on reasonable medical certainty I have to follow good practice guidelines and I cannot read their minds. Besides, I warn any patient on any substance of abuse that I will never replace lost scripts for those types of meds so don't even ask me.

I emphasize this because I've seen too many narcissistic and egocentric doctors always point to disagreeing patients as being wrong when that is not always the case. Several patients have reactions that are not the norm.

The bottom line is one could get a better reaction from a tradename med vs a generic med vs a generic med from a different manufacturer of the other generic. If so, it's likely due to the excipient. Manufacturing processes differ and the medication from one company may not be 100% the same in terms of bioequivalence but per FDA guidelines they must be darned close (e.g. 98%). The odds of getting a different reaction are rare, but I've seen them happen to the degree where one cannot assume it'll never happen. If one does have a good reaction to one and not another, the specific manufacturer of that specific med must be identified and the patient must only continue that med from that specific manufacturer or avoid the med from the other manufacturer where they did not have as good an experience.
 
Last edited:
Top